Advertisement

Direct oral anticoagulant use in gynecologic oncology: A Society of Gynecologic Oncology Clinical Practice Statement

  • Gregory M. Gressel
    Correspondence
    Corresponding author at: Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women's Health, Montefiore Medical Center, Albert Einstein College of Medicine, 1695 Eastchester Road, Bronx, NY 10471, United States of America.
    Affiliations
    Division of Gynecologic Oncology, Department of Obstetrics & Gynecology and Women's Health, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, United States of America
    Search for articles by this author
  • Jenna Z. Marcus
    Affiliations
    Division of Gynecologic Oncology, Department of Obstetrics & Gynecology and Reproductive Health, Rutgers New Jersey Medical School, Newark, NJ, United States of America
    Search for articles by this author
  • Mary M. Mullen
    Affiliations
    Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Washington University School of Medicine, St. Louis, MO, United States of America
    Search for articles by this author
  • Abdulrahman K. Sinno
    Affiliations
    Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, United States of America
    Search for articles by this author
Published:November 28, 2020DOI:https://doi.org/10.1016/j.ygyno.2020.11.020

      Highlights

      • DOACs effective as LMWH for treatment of cancer-associated thrombosis.
      • DOACs linked with higher bleeding risk, specifically with gastro and genitourinary cancers.
      • Apixaban has similar safety profile to LMWH after major abdominopelvic surgery.
      • Future studies to examine safety and efficacy in patients with gynecologic malignancy.

      Abstract

      Venous thromboembolism (VTE) is a common cause of morbidity and mortality in women with gynecologic malignancies. This practice statement provides clinical data and overall quality of evidence regarding the use of direct oral anticoagulants (DOACs) in this patient population. Specifically, it reviews patient selection, safety measures, and nuances of perioperative use of these medications. The scope of this document is limited to DOAC use in gynecologic oncology rather than a broad discussion of VTE prophylaxis and management in general. The following recommendations and examination of extant data are based on DOAC trials conducted primarily in mixed populations with different cancer subtypes. Many of these trials include few, or no, women with gynecologic cancer. However, because there is very limited data in gynecologic cancer-specific populations, the results of these studies represent the best available evidence to support treatment recommendations in our patients. The members of the Society of Gynecologic Oncology (SGO) Clinical Practice Committee believe that the results of these studies may be extrapolated, with caution, to VTE treatment and prophylaxis for patients with gynecologic cancer.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cohen A.
        • Lim C.S.
        • Davies A.H.
        Venous thromboembolism in gynecological malignancy.
        Int. J. Gynecol. Cancer. 2017; 27: 1970-1978
        • Kushnir C.L.
        • Diaz-Montes T.P.
        Perioperative care in gynecologic oncology.
        Curr. Opin. Obstet. Gynecol. 2013; 25: 23-28
        • Li A.
        • Garcia D.A.
        • Lyman G.H.
        • Carrier M.
        Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis.
        Thromb. Res. 2019; 173: 158-163
        • Barber E.L.
        • Clarke-Pearson D.L.
        Prevention of venous thromboembolism in gynecologic oncology surgery.
        Gynecol. Oncol. 2017; 144: 420-427
        • Akl E.A.
        • Vasireddi S.R.
        • Gunukula S.
        • et al.
        Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
        Cochrane Database Syst. Rev. 2011; 2CD006649
        • Kearon C.
        • Akl E.A.
        • Ornelas J.
        • et al.
        Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report.
        Chest. 2016; 149 (Epub 2016 Jan 7): 315-352https://doi.org/10.1016/j.chest.2015.11.026
        • Guyatt G.H.
        • Oxman A.D.
        • Vist G.E.
        • et al.
        GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.
        BMJ. 2008; 336: 924-926
        • Lee A.Y.Y.
        • Kamphuisen P.W.
        • Meyer G.
        • et al.
        Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial.
        J. Am. Med. Assoc. 2015; 314: 677-686https://doi.org/10.1001/jama.2015.9243
        • Lee A.Y.Y.
        • Levine M.N.
        • Baker R.I.
        • et al.
        Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
        N. Engl. J. Med. 2003; 349: 146-153https://doi.org/10.1056/NEJMoa025313
        • Hull R.D.
        • Pineo G.F.
        • Brant R.F.
        • et al.
        Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer.
        Am. J. Med. 2006; 119: 1062-1072https://doi.org/10.1016/j.amjmed.2006.02.022
        • Meyer G.
        • Marjanovic Z.
        • Valcke J.
        • et al.
        Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.
        Arch. Intern. Med. 2002; 162: 1729-1735
        • Carrier M.
        • Cameron C.
        • Delluc A.
        • Castellucci L.
        • Khorana A.A.
        • Lee A.Y.Y.
        Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis.
        Thromb. Res. 2014; 134: 1214-1219https://doi.org/10.1016/j.thromres.2014.09.039
        • Kahale L.A.
        • Hakoum M.B.
        • Tsolakian I.G.
        • et al.
        Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
        Cochrane Database Syst. Rev. 2018; 6CD006650
        • Martinez-Zapata M.J.
        • Mathioudakis A.G.
        • Mousa S.A.
        • Bauersachs R.
        Tinzaparin for long-term treatment of venous thromboembolism in patients with cancer: a systematic review and meta-analysis.
        Clin. Appl. Thromb. Hemost. 2018; 24: 226-234
        • Posch F.
        • Königsbrügge O.
        • Zielinski C.
        • Pabinger I.
        • Ay C.
        Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants.
        Thromb. Res. 2015; 136: 582-589https://doi.org/10.1016/j.thromres.2015.07.011
        • Key N.S.
        • Bohlke K.
        • Falanga A.
        Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update summary.
        J. Oncol. Pract. 2019; 15: 661-664
        • Khorana A.A.
        • Noble S.
        • Lee A.Y.Y.
        • et al.
        Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
        J. Thromb. Haemost. 2018; 16: 1891-1894
        • Streiff M.B.
        • Holmstrom B.
        • Angelini D.
        • et al.
        NCCN Guidelines® insights cancer-associated venous thromboembolic disease, version 1.2020 featured updates to the NCCN guidelines.
        J. Natl. Compr. Cancer Netw. 2018; 16: 1289-1303
        • Ageno W.
        • Haas S.
        • Weitz J.I.
        • et al.
        Characteristics and management of patients with venous thromboembolism: the GARFIELD-VTE registry.
        Thromb. Haemost. 2019; 119: 319-327
        • Raskob G.E.
        • Van Es N.
        • Verhamme P.
        • et al.
        Edoxaban for the treatment of cancer-associated venous thromboembolism.
        N. Engl. J. Med. 2018; 378: 615-624
        • Young A.M.
        • Marshall A.
        • Thirlwall J.
        • et al.
        Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D).
        J. Clin. Oncol. 2018; 36: 2017-2023
        • Brunetti N.D.
        • Gesuete E.
        • De Gennaro L.
        • et al.
        Direct oral anti-coagulants compared with vitamin-K inhibitors and low-molecular-weight-heparin for the prevention of venous thromboembolism in patients with cancer: a meta-analysis study.
        Int. J. Cardiol. 2017; 230: 214-221
        • Agnelli G.
        • Becattini C.
        • Meyer G.
        • et al.
        Apixaban for the treatment of venous thromboembolism associated with cancer.
        N. Engl. J. Med. 2020; 382: 1599-1607
        • Francis C.W.
        Prevention of venous thromboembolism in hospitalized patients with cancer.
        J. Clin. Oncol. 2017; 230: 214-221https://doi.org/10.1016/j.ijcard.2016.12.168
        • Kroger K.
        • Weiland D.
        • Ose C.
        • et al.
        Risk factors for venous thromboembolic events in cancer patients.
        Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2006; 17: 297-303
        • Kahn S.R.
        • Lim W.
        • Dunn A.S.
        • et al.
        Prevention of VTE in nonsurgical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141
        • Leizorovicz A.
        • Cohen A.T.
        • Turpie A.G.G.
        • Olsson C.G.
        • Vaitkus P.T.
        • Goldhaber S.Z.
        Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
        Circulation. 2004; 110: 874-879
        • Carrier M.
        • Khorana A.A.
        • Moretto P.
        • Le Gal G.
        • Karp R.
        • Zwicker J.I.
        Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer.
        Am. J. Med. 2014; 127 (82-6.e1)
        • Cohen A.T.
        • Davidson B.L.
        • Gallus A.S.
        • et al.
        Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.
        Br. Med. J. 2006; 332: 325-329
        • Samama M.M.
        • Cohen A.T.
        • Darmon J.Y.
        • et al.
        A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients.
        N. Engl. J. Med. 1999; 341: 793-800
        • Lyman G.H.
        • Eckert L.
        • Wang Y.
        • Wang H.
        • Cohen A.
        Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis.
        Oncologist. 2013; 18: 1321-1329
        • Khorana A.A.
        • Dalal M.
        • Lin J.
        • Connolly G.C.
        Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States.
        Cancer. 2013; 119: 648-655
        • Carrier M.
        • Abou-Nassar K.
        • Mallick R.
        • et al.
        Apixaban to prevent venous thromboembolism in patients with cancer.
        N. Engl. J. Med. 2019; 380: 711-719
        • Khorana A.A.
        • Soff G.A.
        • Kakkar A.K.
        • et al.
        Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer.
        N. Engl. J. Med. 2019; 380: 720-728
        • Di Nisio M.
        • Candeloro M.
        • Rutjes A.W.S.
        • Porreca E.
        Venous thromboembolism in cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis.
        J. Thromb. Haemost. 2018; 16: 1336-1346
        • Salinaro J.R.
        • McQuillen K.
        • Stemple M.
        • et al.
        Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
        Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc. 2020; 30: 491-497
        • Khorana A.A.
        • Kuderer N.M.
        • Culakova E.
        • Lyman G.H.
        • Francis C.W.
        Development and validation of a predictive model for chemotherapy-associated thrombosis.
        Blood. 2008; 111: 4902-4907
        • van Es N.
        • Franke V.F.
        • Middeldorp S.
        • Wilmink J.W.
        • Buller H.R.
        The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer.
        Thromb. Res. 2017; 150: 30-32
        • Mansfield A.S.
        • Tafur A.J.
        • Wang C.E.
        • Kourelis T.V.
        • Wysokinska E.M.
        • Yang P.
        Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer.
        J. Thromb. Haemost. 2016; 14: 1773-1778
        • Gressel G.M.
        • Turker L.
        • Dioun S.M.
        • McGinn A.P.
        • Nevadunsky N.S.
        Characterization of risk factors and timing of venous thromboembolism in patients with uterine serous carcinoma.
        Obstet. Gynecol. 2018; 132: 1130-1136
        • Riondino S.
        • Ferroni P.
        • Zanzotto F.M.
        • Roselli M.
        • Guadagni F.
        Predicting VTE in cancer patients: candidate biomarkers and risk assessment models.
        Cancers (Basel). 2019; 11
        • Noble S.
        • Alikhan R.
        • Robbins A.
        • Macbeth F.
        • Hood K.
        Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer: comment.
        J. Thromb. Haemost. 2017; 15: 590-591
        • Ay C.
        • Dunkler D.
        • Marosi C.
        • et al.
        Prediction of venous thromboembolism in cancer patients.
        Blood. 2010; 116 ([Internet]. Available from): 5377-5382
        • Verso M.
        • Agnelli G.
        • Barni S.
        • Gasparini G.
        • LaBianca R.
        A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score.
        Intern. Emerg. Med. 2012; 7 ([Internet]): 291-292https://doi.org/10.1007/s11739-012-0784-y
        • Cella C.A.
        • Di Minno G.
        • Carlomagno C.
        • et al.
        Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV study.
        Oncologist. 2017; 22 ([Internet]): 601-608https://doi.org/10.1634/theoncologist.2016-0246
        • Gerotziafas G.T.
        • Taher A.
        • Abdel-Razeq H.
        • et al.
        A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-cancer-associated thrombosis study.
        Oncologist. 2017; 22: 1222-1231
        • Muñoz Martín A.J.
        • Ortega I.
        • Font C.
        • et al.
        Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer.
        Br. J. Cancer. 2018; 118: 1056-1061
        • Pabinger I.
        • van Es N.
        • Heinze G.
        • et al.
        A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts.
        Lancet Haematol. 2018; 5: e289-e298
      1. ENOXACAN Study Group. Br. J. Surg. 1997; 84: 1099-1103
        • Mismetti P.
        • Laporte S.
        • Darmon J.Y.
        • Buchmuller A.
        • Decousus H.
        Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery.
        Br. J. Surg. 2001; 88: 913-930
        • Akl E.A.
        • Terrenato I.
        • Barba M.
        • et al.
        Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis.
        Arch. Intern. Med. 2008; 168: 1261-1269
        • DeBernardo R.L.J.
        • Perkins R.B.
        • Littell R.D.
        • Krasner C.N.
        • Duska L.R.
        Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
        Obstet. Gynecol. 2005; 105: 1006-1011
        • Lassen M.R.
        • Raskob G.E.
        • Gallus A.
        • Pineo G.
        • Chen D.
        • Hornick P.
        Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
        Lancet. 2010; 375: 807-815
        • Guntupalli S.R.
        • Brennecke A.
        • Behbakht K.
        • et al.
        Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial.
        JAMA Netw. Open. 2020; 3e207410
        • Douketis J.D.
        • Spyropoulos A.C.
        • Spencer F.A.
        • et al.
        Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
        Chest. 2012; 141: e326S-e350S
        • Douketis J.D.
        • Spyropoulos A.C.
        • Kaatz S.
        • et al.
        Perioperative bridging anticoagulation in patients with atrial fibrillation.
        N. Engl. J. Med. 2015; 373: 823-833
        • Douketis J.D.
        • Spyropoulos A.C.
        • Duncan J.
        • et al.
        Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant.
        JAMA Intern. Med. 2019; 179: 1469-1478
        • Schulman S.
        • Carrier M.
        • Lee A.Y.Y.
        • et al.
        Perioperative management of dabigatran: a prospective cohort study.
        Circulation. 2015; 132: 167-173
        • Douketis J.D.
        • Foster G.A.
        • Crowther M.A.
        • Prins M.H.
        • Ginsberg J.S.
        Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy.
        Arch. Intern. Med. 2000; 160: 3431-3436
        • Raval A.N.
        • Cigarroa J.E.
        • Chung M.K.
        • et al.
        Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association.
        Circulation. 2017; 135: e604-e633
      2. Praxbind (Idarucizumab) Prescribing Information. Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut2018 ([Internet]. Available from)
      3. Andexxa (Andexanet Alfa) Prescribing Information. Portola Pharmaceuticals, Inc, San Francisco, CA2017
        • Pollack C.V.J.
        • Reilly P.A.
        • van Ryn J.
        • et al.
        Idarucizumab for dabigatran reversal - full cohort analysis.
        N. Engl. J. Med. 2017; 377: 431-441
        • Connolly S.J.
        • Crowther M.
        • Eikelboom J.W.
        • et al.
        Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors.
        N. Engl. J. Med. 2019; 380: 1326-1335
        • Hakeam H.A.
        • Al-Sanea N.
        Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs).
        J. Thromb. Thrombolysis. 2017; 43: 343-351
        • Byon W.
        • Nepal S.
        • Schuster A.E.
        • Shenker A.
        • Frost C.E.
        Regional gastrointestinal absorption of apixaban in healthy subjects.
        J. Clin. Pharmacol. 2018; 58: 965-971
        • McBane 2nd, R.D.
        • Wysokinski W.E.
        • Le-Rademacher J.G.
        • et al.
        Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial.
        J. Thromb. Haemost. 2020; 18: 411-421
        • Farge D.
        • Frere C.
        • Connors J.M.
        • et al.
        2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
        Lancet Oncol. 2019; 20: e566-e581
      4. Eliquis (Apixaban) Prescribing Information. Bristol-Myers Squibb Company and Pfizer, Inc, Princeton, New Jersey2019
      5. Savaysa (Edoxaban) Prescribing Information. Daiichi Sankyo, Inc, Basking Ridge, New Jersey2019
      6. Xarelto (Rivaroxaban) Prescribing Information. Janssen Pharmaceuticals, Inc, Titusville, New Jersey2019
      7. Pradaxa (Dabigatran) Prescribing Information. Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut2019
        • Douketis J.D.
        • Spyropoulos A.C.
        • Anderson J.M.
        • et al.
        The perioperative anticoagulant use for surgery evaluation (PAUSE) study for patients on a direct oral anticoagulant who need an elective surgery or procedure: design and rationale.
        Thromb. Haemost. 2017; 117: 2415-2424